Netakimab for the treatment of psoriatic arthritis: 3-year results of the phase III BCD-085-8/PATERA study
Authors:
- T. V. KorotaevaTKT. V. Korotaeva
- V. I. MazurovVMV. I. Mazurov
- A. M. LilaALA. M. Lila
- I. Z. GaidukovaIGI. Z. Gaidukova
- A. L. BakulevABA. L. Bakulev
- A. V. SamtsovASA. V. Samtsov
- V. R. KhairutdinovVKV. R. Khairutdinov
- A. V. Zinkina-OrikhanAZA. V. Zinkina-Orikhan
- Yu. N. LinkovaYLYu. N. Linkova
- A. V. EremeevaAEA. V. Eremeeva
Open Access
- 20 August 2024
- journal article
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (4) , 33-42
Abstract
This article presents the results of the 3-year use of netakimab (NTK), a monoclonal antibody against interleukin 17, in patients with psoriatic arthritis (PsA) as part of the phase III PATERA study. Objective: to evaluate the long-term efficacy and safety of NTK in patients with PsA over a period of 3 years. Material and methods. PATERA is a double-blind, multicenter, randomized, phase III clinical trial. 194 patients with active PsA were randomized 1:1 to NTX or placebo/NTX. NTX/placebo was administered at weeks 0, 1, 2, 4, 6, 8, 10 and 14. Placebo patients who did not achieve a 20% improvement according to ACR criteria (ACR20) at week 16 received NTX at weeks 18 and 22. Patients who achieved ACR20 received placebo at weeks 18 and 22. Subsequently, all patients received NTX. At week 54, patients who did not meet ACR20 criteria were withdrawn from the study and the remaining patients were treated in the extension phase. The total duration of NTX use in all groups was 3 years. Results and discussion. Therapeutic response achieved in the first year of treatment was maintained in the extended phase of the study. Against the background of NTX use, a significant long-term decrease in clinical manifestations of PsA was observed. Adverse events occurred mainly in the form of laboratory abnormalities and infectious diseases, which were mostly mild to moderate. Antibodies against NTK were detected in 9.3% of patients and in most cases they were formed at the end of the first and beginning of the second year of therapy. Conclusion. NTK showed a favorable safety profile with long-term use over 3 years. The clinical effect on all manifestations of PsA was maintained in most patients over a long period of time without significant loss of response.Keywords
This publication has 33 references indexed in Scilit:
- Psoriasis and Psoriatic Arthritis Have a Major Impact on Quality of Life and Depressive Symptoms: A Cross-Sectional Study of 300 PatientsRheumatology and Therapy, 2023
- Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three IndicationsRheumatology and Therapy, 2022
- Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USA—a retrospective study of claims data from 2009 TO 2020Clinical Rheumatology, 2021
- Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical TrialDermatology and Therapy, 2021
- Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive ReviewAmerican Journal of Clinical Dermatology, 2020
- Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results from the Phase 3 FUTURE 1 StudyACR Open Rheumatology, 2019
- Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical TrialsArthritis Care & Research, 2018
- Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3Journal of the American Academy of Dermatology, 2018
- Obesity, Waist Circumference, Weight Change, and the Risk of Psoriasis in WomenArchives of internal medicine (1960), 2007
- Classification criteria for psoriatic arthritis: Development of new criteria from a large international studyArthritis & Rheumatism, 2006